
Leptin mediates the increase in blood pressure associated with obesity

Cell, 2014; 159(6):1404-1416

©2014 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Originally published at:
http://doi.org/10.1016/j.cell.2014.10.058
Leptin Mediates the Increase in Blood Pressure Associated with Obesity

Stephanie E. Simonds, 1 Jack T. Pryor, 2, 3 Eric Ravussin, 4 Frank L. Greenway, 4 Ralph Daleone, 5 Andrew M. Allen, 6 Jaspreet Bassi, 6 Joel K. Elmquist, 7 Julia M. Keogh, 8 Elana Henning, 8 Martin G. Myers, Jr., 9 Julio Licinio, 10 Russell D. Brown, 1 Pablo J. Enriori, 1 Stephen O’Rahilly, 8 Scott M. Sternson, 11 Kevin L. Grove, 12 David C. Spanswick, 1, 2 I. Sadaf Farooqi, 8,* and Michael A. Cowley 1, *

1Department of Physiology, Monash Obesity and Diabetes Institute, Monash University, Clayton, VIC 3800, Australia
2Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
3Neurosolutions Ltd., Coventry CV4 7ZS, UK
4The Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
5Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA
6Department of Physiology, The University of Melbourne, Victoria 3010, Australia
7Division of Endocrinology & Metabolism, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
8University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
9Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
10Mind and Brain Theme, South Australian Health and Medical Research Institute and Department of Psychiatry, School of Medicine, Flinders University, Adelaide, SA 5001, Australia
11Janelia Farm Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA
12Division of Diabetes, Obesity & Metabolism, Oregon National Primate Research Center, Portland, OR 97239, USA
*Correspondence: isf20@cam.ac.uk (I.S.F.), michael.cowley@monash.edu (M.A.C.)
http://dx.doi.org/10.1016/j.cell.2014.10.058
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

SUMMARY

Obesity is associated with increased blood pressure (BP), which in turn increases the risk of cardiovascular diseases. We found that the increase in leptin levels seen in diet-induced obesity (DIO) drives an increase in BP in rodents, an effect that was not seen in animals deficient in leptin or leptin receptors (LepR). Furthermore, humans with loss-of-function mutations in leptin and the LepR have low BP despite severe obesity. Leptin’s effects on BP are mediated by neuronal circuits in the dorsomedial hypothalamus (DMH), as blocking leptin with a specific antibody, antagonist, or inhibition of the activity of LepR-expressing neurons in the DMH caused a rapid reduction of BP in DIO mice, independent of changes in weight. Re-expression of LepRs in the DMH of DIO LepR-deficient mice caused an increase in BP. These studies demonstrate that leptin couples changes in weight to changes in BP in mammalian species.

INTRODUCTION

Obesity increases the risk for hypertension and is a major driver of morbidity and mortality due to cardiovascular diseases (Dus-
POMC neurons become unresponsive to leptin in obesity, and leptin can act independently of MC4R signaling (Enriori et al., 2011; Patterson et al., 2011; Scott et al., 2009). Therefore, leptin’s effects beyond the melanocortin circuits need to be investigated. The dorsomedial hypothalamus (DMH) is critical for leptin’s ability to regulate brown adipose tissue (BAT) temperature and the cardiovascular system (Enriori et al., 2011; Fontes et al., 2001; Horiuchi et al., 2006; Marsh et al., 2003; Rezai-Zadeh et al., 2014).

Here, we investigated the development of obesity-induced hypertension. We demonstrate that, in DIO mice, increasing levels of leptin directly lead to an increase in HR and BP and that blocking the actions of leptin reverses these effects via neural circuits originating in the DMH. Furthermore, humans with loss-of-function mutations in leptin and its receptor have normal BP despite severe obesity, suggesting that these mechanisms are likely to be preserved in humans.

**RESULTS**

**Weight Gain Increases Leptin Levels, Heart Rate, and Blood Pressure**

The temporal association between weight gain, changes in circulating leptin levels, HR, and BP were first examined. Four-week-old C57Bl/6J mice on a chow diet were implanted with radiotelemetric BP probes; baseline measurements were recorded at 6 weeks. As BW increased (Figure 1A), plasma leptin levels also progressively increased (Figure 1B). After 4 weeks of HFD, HR became significantly elevated (Figure 1C) and remained elevated throughout the 20 week recording period compared to chow fed mice. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were significantly elevated after 12 weeks of HFD (Figures 1D and 1E), subsequent to the rise in plasma leptin concentration. When HFD-fed mice were returned to a chow diet following 20 weeks of HFD feeding, mice

---

**Figure 1. Temporal Relationship between Changes in Weight Gain, Plasma Leptin Concentrations, and Blood Pressure**

(A) Body weight (g), of mice from 4 weeks of age ad libitum fed either a high-calorie diet (DIO mice) or chow diet (lean mice) for 20 weeks. Following this 20 week period, DIO mice were switched to chow diet for 4 weeks; n = 3–7.

(B–E) (B) Plasma leptin concentration (ng/ml), (C) heart rate BPM (beats per min), (D) SBP, and (E) DBP (mmHg) at 2 week intervals, beginning at baseline (4-week-old mice). Following this baseline period, mice were fed a high-calorie diet (DIO) or chow diet (lean) for 20 weeks ad libitum. After 20 weeks of HFD in DIO mice, these mice were switched to chow diet for 4 weeks. n = 3–18.

Values mean ± SEM; two-way AVOVA, Bonferroni post hoc test. *p < 0.05, **p < 0.01, and ***p < 0.001.
lost 3.9 g in the first week, 3.9 g in the second week, 3.4 g in the third week, and 0.4 g in the fourth week (Figure 1A). DBP reduced after 1 week (Figure 1E), and SBP (Figure 1D) and HR (Figure 1C) reduced after 2 weeks of chow feeding. These findings suggest that leptin appears to increase before HR and BP increases in DIO, effects that are reversed with weight loss.

**Leptin Signaling Is Required for Obesity-Induced Increases in Blood Pressure**

We examined whether the effects seen in DIO mice are dependent upon leptin signaling, using mice lacking leptin (ob/ob) or the LepR (db/db). HFD-fed ob/ob and db/db mice were significantly (p < 0.001) heavier than HFD-fed DIO and chow-fed lean, ob/ob, and db/db mice (Figure 2A). Despite the increased severity of obesity in the ob/ob and db/db mice, only DIO mice exhibited elevated HR, SBP, and DBP (Figures 2B–2G), demonstrating that increased BW alone is not the cause of the increase in BP in obesity. There was a greater difference in HR and BP between DIO mice to other mice during the dark period compared to the light period (Figures S1A–S1C available online). The increase in cardiovascular parameters in DIO mice was not due to increased activity (Figures S1D and S1E).

Strong correlations were found in C57Bl/6J mice between plasma leptin concentration and HR (Figure 2H), DBP (Figure 2J), and SBP (Figure 2I). No correlation was found between plasma insulin concentration and HR, SBP, or DBP (Figures S1G–S1I). To examine the direct effect of leptin on BP, leptin-deficient ob/ob mice were treated for 11 days with either leptin or vehicle. After 11 days of treatment, the average plasma leptin concentration of ob/ob mice treated with leptin was 27.7 ± 2.9 ng/ml compared to 36.3 ± 4.9 ng/ml in DIO mice and 6.6 ± 1.1 ng/ml in lean mice (Figure S1F). Exogenous leptin treatment in ob/ob mice progressively decreased BW (Figure S1M) and food intake (Figure S1N) compared to leptin-treated db/db mice and vehicle-treated ob/ob mice. Despite this decrease in BW, leptin treatment increased HR (Figures 2K and 2L) and SBP (Figures 2M and 2N) in leptin-treated ob/ob mice compared to leptin-treated db/db mice and vehicle-treated ob/ob mice. DBP also increased in ob/ob leptin-treated mice, however, not to the same extent as SBP (Figures 2O and 2P). The magnitude of the increase in HR and BP in leptin-treated ob/ob mice decreased with time, coincident with their substantial reduction in BW. The 24 hr circadian rhythm of HR (Figure S2J), SBP (Figure S2K), and DBP (Figure S1L) of leptin-treated ob/ob mice was increased toward the baseline recordings of DIO mice. These changes were not explained by increased activity (Figure S1O).

**Inhibition of Leptin Signaling Reduces Elevated BP**

Peripheral administration of a leptin antibody into DIO mice for 5 days caused a significant reduction in HR (Figure 3A), SBP (Figure 3B), and DBP (Figure 3C), although no change in BW was observed (Figure 3D). Central administration of a leptin receptor antagonist (LRA) into the lateral ventricle (LV) of hypertensive DIO mice over a 7 day period significantly reduced the elevated HR (p < 0.001; Figure 3E). By the seventh day of LRA treatment, HR was comparable to the average HR of lean animals (Figures 3F and S2A). Systolic BP also progressively decreased when DIO mice were treated with the LRA, and by day 5 of LRA...
treatment, SBP was significantly (p ≤ 0.05) decreased compared to vehicle-treated DIO mice (Figure 3G). By the seventh day of LRA treatment, SBP was significantly (p < 0.05) lower compared to the SBP at baseline in DIO mice and was comparable to the baseline SBP of lean mice (Figures S3H and S2B). SBP increased after LRA treatment ended. DBP also decreased throughout the LRA treatment period (Figures 3I, 3J, and S2C).

These changes were seen despite the absence of a significant change in FI (Figure 3K), indicating that these changes are mediated by blocking the effects of leptin signaling rather than through changes in FI and BW.

**Leptin Modulates BP via Neural Circuits in the Dorsomedial Hypothalamus**

To determine whether leptin’s effects on BP and HR were mediated by neurons in the DMH, the LRA was injected directly into the DMH of hypertensive DIO mice daily over 7 days. LRA treatment in the DMH decreased HR (Figures 4A, 4B, and S3A) and SBP (Figures 4C, 4D, and S3B) by day 7 of treatment. No significant change in DBP (Figures 4E, 4F, and S3C) was observed. Furthermore, injection of an AAV expressing a short hairpin RNA directed against the LepR (Hommel et al., 2006) in the DMH of DIO mice led to a sustained decrease in SBP (Figures 4G, 4H, and S3D) after 4 weeks. Utilizing mice in which the LepR is flanked by loxP sites and can be deleted by an AAV Cre, HFD for 20 weeks induced increased SBP at baseline, whereas AAV Cre administration into the DMH (hence deleting the LepR in only the DMH regions) decreased SBP (Figure 4I). Additionally, we examined the effects of reactivation of the LepR by injection of an AAV-expressing Cre recombinase into the DMH of normotensive morbidly obese LepR null mice (expressing a loxP flanked STOP codon in front of the LepR, called LepR transcriptional blocker or “LepR TB” mice; Berglund et al., 2012). Both HR (Figure 4J) and SBP (Figure 4K) increased rapidly after LepR expression was reactivated in just the DMH of obese LepR-deficient mice.

**Depolarization of DMH LepR-Expressing Neurons**

To determine the electrophysiological effect of leptin on DMH neurons, we recorded the electrical activity of neurons expressing LepR in LepR-Cre-YFP mice (Leshan et al., 2012). Whole-cell recordings were obtained from 34 DMH neurons expressing LepR. Application of 100 nM leptin induced membrane depolarization and/or an increase in spontaneous action potential firing rate in 38.2% of recorded neurons (Figure 5A). Leptin induced a mean peak amplitude depolarization of 4.9 ± 1.0 mV from a mean resting potential of −49.9 ± 3.1 mV to a new steady-state membrane potential of −45.0 ± 2.7 mV (p = 0.0004). Leptin-induced excitation was associated with an increase in firing rate from a mean control basal level of 0.48 ± 0.28 Hz to 0.64 ± 0.34 Hz in the presence of leptin (n = 5), effects that were at least in part reversible after washout of leptin (p = 0.59). In two neurons, leptin induced sub- and suprathreshold oscillations in membrane potential (Figure S4A).

Voltage-current relations, generated in response to a range of depolarizing and hyperpolarizing rectangular-wave current pulses (−150 to +100 pA, 1,000 ms duration) revealed that leptin-induced excitation was principally associated with a trend for a decrease (p = 0.86) in neuronal input resistance from 841 ± 111 MΩ in the absence to 743 ± 138 MΩ in the presence of leptin. Plots of the voltage-current relations revealed extrapolated reversal potentials for leptin-induced excitation around −35 mV (Figure 5B). Taken together, these data suggest that leptin-induced excitation is mediated via activation of one or more nonselective cation conductances. In addition to these effects on membrane input conductance, leptin also induced modulation of intrinsic subthreshold active conductance in a subpopulation of DMH neurons. In DMH neurons, membrane depolarization from negative holding potentials (< −65 mV) or depolarization at the offset of the membrane response to hyperpolarization from potentials close to resting potential (−45 to −50 mV) evoked a transient depolarizing potential consistent with activation of a low-threshold T-type calcium conductance. In the presence of leptin, this potential was prolonged (Figure 5B), the half-time to decay increasing from 132 ± 59 ms in the absence to 179 ± 61 ms in the presence of leptin. These data are consistent with leptin modulating intrinsic active conductances in a subpopulation of DMH neurons. In addition to these postsynaptic effects, leptin induced an increase in spontaneous excitatory postsynaptic potentials (EPSPs) in a subpopulation (n = 2) of DMH neurons (Figure S4B). The mean frequency of spontaneous EPSPs increased from 0.07 ± 0.02 Hz to 0.31 ± 0.11 Hz in the presence of leptin. These EPSPs could be of sufficient magnitude to reach threshold for firing, suggesting that indirect presynaptic effects of leptin on DMH neurons can contribute to leptin-induced increases in neuronal excitability.
Figure 4. The DMH Is Involved in Leptin-Mediated Increases in HR and BP

(A) Daily change in HR (BPM) from baseline in DIO mice treated in the DMH with aCSF or a LRA. Two-way ANOVA, Bonferroni post hoc test, n = 4.

(B) Total 24 hr HR (BPM) after 7 days of LRA treatment in the DMH of DIO mice compared to lean and DIO mice at baseline. t test paired (DIO baseline versus LRA), unpaired t test. n = 4–37.

(C) Daily change in SBP (mmHg) from baseline in DIO mice treated in the DMH with aCSF or a LRA. Two-way ANOVA, Bonferroni post hoc test, n = 4.

(D) Total 24 hr SBP (mmHg) after 7 days of LRA treatment in the DMH of DIO mice compared to lean and DIO mice at baseline. t test paired (DIO baseline versus LRA), unpaired t test. n = 4–37.

(E) Daily change in DBP (mmHg) from baseline in DIO mice treated in the DMH with aCSF or a LRA. Two-way ANOVA, Bonferroni post hoc test, n = 4.

(F) 24 hr DBP (mmHg) after 7 days of LRA treatment in the DMH of DIO mice compared to lean and DIO mice at baseline. t test paired (DIO baseline versus LRA), unpaired t test. n = 4–37.

(G) Percentage change in SBP (mmHg) of DIO mice, following control (scrambled AAV) or leptin receptor knockdown AAV into the DMH. Two-way ANOVA, Bonferroni post hoc test, n = 4–6.

(H) Quantitative analysis from day 31 onward of AAV scrambled control-injected DIO mice and AAV LepR knockdown-treated DIO mice. t test, n = 4–6.

(I) 24 hr circadian rhythm of SBP (mmHg) at baseline and then following the seventh day of AAV Cre injection into the DMH of LepR flox mice. Two-way ANOVA, Bonferroni post hoc test, n = 4.

(J) 24 hr circadian rhythm of heart rate (BPM) at baseline and then following the seventh day of AAV Cre injection into the DMH of LepR flox TB mice. Two-way ANOVA, Bonferroni post hoc test, n = 4.

(K) 24 hr circadian rhythm of SBP (mmHg) at baseline and then following the seventh day of AAV Cre injection into the DMH of LepR flox TB mice. Two-way ANOVA, Bonferroni post hoc test, n = 4.

Values represent mean ± SEM. *p < 0.05 and **p < 0.01. See also Figure S3.
In Vivo Inhibition of LepR DMH-Expressing Neurons Decreases BP

In vivo, the effects of directly altering the neuronal activity of LepR-expressing DMH neurons were assessed using engineered pharmacologically selective chimeric ion channels for activating and silencing neuron activity (Magnus et al., 2011). Briefly, this technology requires the injection of a virus, which only infects and replicates in a Cre-dependent manner, into Cre-expressing mice. The virus drives the Cre-dependent expression of a modified ion channel, containing a PSAM element. After injection (intraperitoneal injection), the otherwise inert molecule PSEM binds to an ion channel that contains a PSAM element, which opens the ion pore and allows ion flux across the cell membrane, which depolarizes or hyperpolarizes virus-infected, Cre-expressing neurons. Using male 20-week-old chow-fed lean LepR-Cre-YFP transgenic mice (Leshan et al.,...
we investigated whether activation of DMH LepR-expressing neurons could increase HR and BP. Lean LepR-Cre-YFP mice were injected bilaterally with activator virus, an engineered ionotropic serotonin receptor packaged in an AAV2 (pSyn::Flex-rev-PSAM Y115F:5HT3 HC-IRES-GFP) into the DMH. In lean mice 21 days after virus injection, twice daily intraperitoneal (i.p.) administration of the receptor ligand PSEM (i.p. 2X daily [5 mg/kg]) for 3 days significantly increased HR and BP (p < 0.05; Figures S4 D–S4F) compared to vehicle-treated mice. In DIO LepR-Cre-YFP mice, an inhibitory virus, an engineered ionotropic glycine receptor packaged into an AAV2 (AAV2: pSyn::Flex-rev-PSAM L141F:GlyR-IRES-GFP) was administered bilaterally into the DMH. Compared to vehicle-treated mice, PSEM acutely decreased HR (Figures 5 C and 5D) and SBP (Figures 5 E and 5F), but no significant change in DBP was observed (Figures 5 G and 5H). Sub-chronic daily treatment with PSEM reduced HR (by 72.6 ± 5.6 bpm) and SBP by 6.1 ± 1.7 mmHg and DBP over 3 days (Figures S5 I, S5 J, and S5 C), effects which were reversed once PSEM treatment ceased. Treatment of mice with PSEM, prior to virus administration had no effect on HR or BP (Figures S4 G and S4 H). Cumulatively, these findings indicate that leptin signaling is required for the changes in BP seen in DIO and that LepR expressing neurons in the DMH are necessary and sufficient to cause these effects. These data also support the premise that the hypertension induced by leptin in the DMH is due to leptin-induced depolarization of DMH neurons.

Human Leptin and Leptin Receptor Mutations Are Associated with Low Blood Pressure Despite Severe Obesity

Homzygous complete loss-of-function mutations in the gene encoding leptin (LEP) are associated with undetectable leptin levels and severe early-onset obesity in humans (Montague et al., 1997). We measured BP in the fasted rested state in eight age- and BMI-matched controls (Figures 6A; p < 0.05); there was no difference in DBP. A statistically significant attenuation of SBP was also seen in severely obese children who were homozygous for complete loss-of-function mutations in the LEPR gene (n = 12) compared to 48 age- and BMI-matched controls (Figure 6B; p < 0.05) (Table S1). There were no significant differences in resting HR between the groups (data not shown). Administration of recombinant methionyl human leptin to individuals with congenital leptin deficiency leads to significant weight loss (Farooqi et al., 1999; Ozata et al., 1999). In a previously reported experimental paradigm (Galgani et al., 2010), three leptin-deficient adults were studied before and after treatment with recombinant leptin for 19 weeks, which was sufficient to cause 15.5 ± 0.5 kg weight loss. In parallel, three age- and BMI-matched controls were studied before and after a diet and exercise intervention, which achieved a comparable degree of weight loss (14.8 ± 1.76 kg). The three adult leptin-deficient individuals were found to have normal BP despite severe obesity (Figure 6C). Whereas the MAP of the obese control group decreased as expected (Figure 6D), the BP of the leptin-deficient adults did not change. No difference in HR was observed (Figure S5). Similarly, there was no statistically significant change in BP after recombinant leptin administration to leptin-deficient children (data not shown). These studies in rare individuals completely lacking leptin or functioning LEPR support the assertion that leptin is necessary for the increased BP associated with obesity in humans.

DISCUSSION

Leptin Is the Peripheral Signal Linking Weight Gain to Changes in Blood Pressure

Cumulatively, these studies demonstrate that leptin signaling is necessary for obesity-induced increased BP. We have used multiple convergent methods, including making lean mice...
obese, by adding leptin systemically and by restoring LepR to the DMH of LepR-deficient mice. In all these studies, BP increased. Similarly, we have studied reduced leptin signaling in leptin- and LepR-deficient mice, neutralized circulating leptin with a systemic antibody, infused LepR antagonist ICV and intra-DMH; used shRNA to knock down LepR expression; selectively deleted LepR; and inhibited LepR-expressing neurons in the DMH of obese hypertensive mice. In all of these experiments, reducing leptin signaling reduced BP, even in the presence of obesity. Clinical studies in severely obese humans with two different forms of defective leptin signaling show that these observations are relevant to human physiology and pathophysiology.

**Leptin in the DMH Regulates Cardiovascular Function in the Absence of Effects on BW**

Leptin can acutely increase HR, BP, and BAT, even in anesthetized animals, presumably through activation of the SNS (Enriori et al., 2011; Marsh et al., 2003). Intracerebroventricular (ICV) leptin increases SNA to numerous organs, including the lumbar, kidney, and BAT regions (Haynes et al., 1999). Central antagonism of LepR caused a reduction in BP and HR in DIO hypertensive mice. Although early lesion studies confirm the importance of the DMH for the control of energy homeostasis, little is known about the neurochemical phenotype of the neurons present in the DMH (Elmqquist et al., 1999; Lee et al., 2012). The DMH appears to have a critical ability to control thermogenesis and is involved in elevated BAT-mediated thermogenesis found in obese mice (Enriori et al., 2011; Fan et al., 2005; Morrison et al., 2008). In the studies conducted with antagonism or knocking down of the LepR in DIO mice, we did not find significant changes in FI or BW. These results suggest that the DMH LepR-expressing neurons are not essential for leptin’s effects on BW because the mice lost no additional weight when LepRs were inactivated. Although lesion studies have previously demonstrated a critical role of the DMH in the control of BW, we have shown that long-term knockdown of the LepR does not significantly affect BW, despite the significant reduction in BP and previously reported increase in BAT temperature in obesity (Elmqquist et al., 1999; Enriori et al., 2011). Additionally, acute activation or inhibition of LepR-expressing neurons did not change FI or BW.

**Leptin in Humans**

Contrary to our expectations, we did not observe an increase in BP with the administration of leptin to leptin-deficient patients. There are a number of possible explanations. First, the magnitude of leptin’s effect on BP may be too small to be detected given the sensitivity of the tools for measurement of BP in humans and the small number of individuals studied. Notably, despite weight loss with continued leptin administration, we did not see a significant decrease in BP in these patients as would be expected in more common forms of obesity. These effects are comparable to the effects of leptin on total energy expenditure (TEE), another phenotype mediated by sympathetic tone. We have previously shown that, in contrast to weight loss in obese controls where TEE decreases, TEE does not change with leptin administration in leptin deficiency (Galgeri et al., 2010). Whether leptin increases BP (to a small degree) or leptin-deficient individuals respond differently to weight loss cannot be deduced from our data. However, our results are in line with the suggestion that the effect of leptin administration may be to prevent the reduction in BP expected in congenitally leptin-deficient individuals as they lose weight. In previous trials of leptin in common obesity, no effects on BP were observed (Heymsfield et al., 1999). Rosenbaum and Leibel have shown that controlled 10% weight loss in an experimental setting is sufficient to reduce leptin levels and is associated with decreased SNA (Rosenbaum et al., 2005).

**Could Leptin Be Acting Peripherally?**

It is possible that leptin could be producing some of its cardiovascular effects by acting peripherally. LepR are expressed throughout the brain, including the brainstem; additionally, LepR are expressed on cardiac myocytes, the kidney, and arteries, including the coronary arteries (Knudson et al., 2005; Purdham et al., 2004; Serradeil-Le Gal et al., 1997). We treated DIO mice peripherally with a leptin antibody and then in a separate experiment, DIO mice were treated centrally with the LepR antagonist, and in both experiments, similar responses were observed. In mice lacking the LepR, re-expression of the LepR in only the DMH caused a dramatic increase in BP and HR. The opposite effects occurred when the leptin receptors were deleted from only the DMH region in hypertensive mice. Thus, although LepR expression in peripheral regions may play a role, the results presented here clearly demonstrate a key role for the DMH LepR-expressing neurons in mediating the changes in BP in obesity.

**Is Leptin Action in the DMH Mediated by the Melanocortin System?**

Experiments in rodents and humans support a role for melanocortin signaling in the regulation of BP. Central administration of α-MSH increases BP and HR in wild-type mice, but not in Mc4r−/− mice, which maintain a normal BP despite severe obesity (Kuo et al., 2003; Morgan et al., 2008; Tallam et al., 2005). In humans, heterozygous loss-of-function mutations in MC4R are associated with a reduced prevalence of hypertension, low SBP, lower urinary noradrenaline excretion, and reduced peripheral nerve SNA (Greenfield et al., 2009; Sayk et al., 2010). Moreover, systemic administration of a centrally active melanocortin receptor agonist acutely increased BP in obese volunteers (Greenfield et al., 2009). As such, some of leptin’s effects on BP may be mediated by the melanocortin system. However, there are some indications that, in obesity, the POMC neurons in the ARH become nonresponsive to leptin (this has been termed leptin resistance), and this may limit how much the actions of leptin can be transduced by the POMC neurons in the ARH (Enriori et al., 2007; Knight et al., 2010; Münzberg et al., 2004). Previous research has implicated the POMC neurons of the ARH in the regulation of obesity-induced hypertension via activation of the IKK/NF-κB pathway (Purkayastha et al., 2011; Zhang et al., 2006). How POMC neurons interact with the DMH LepR-expressing neurons has not been addressed in these studies, but the DMH LepR-expressing neurons do send direct efferent projections to ARH neurons (Gautron et al., 2014).
et al., 2010). It is possible that the LepR-expressing neurons in the DMH express Mc4r or that the DMH LepR-expressing neurons act through other neurons that express Mc4r ( Liu et al., 2003). The degree to which leptin’s effects on BP in obesity are dependent upon intact melanocortin signaling remains to be determined ( Do Carmo et al., 2011; Harlan et al., 2011).

**DMH Neurons Regulate Autonomic Outflow to the Heart and Peripheral Vasculature**

DMH LepR-expressing neurons are known to project to numerous brain regions, including the PVH (Elmquist et al., 1998; Gautron et al., 2010). DMH neurons also project to other nuclei, including the Raphe pallidus nucleus (RPa) and rostral ventrolateral medulla (RVLM) (Cao and Morrison, 2003; Horiiuchii et al., 2004; Simonds and Cowley, 2013). Microinjection of leptin into the DMH of anesthetized rats can induce an acute increase in HR and BP (Marsh et al., 2003). The DMH-RPa connection has already been recognized to be important in the regulation of BAT thermogenesis in response to leptin (Zhang et al., 2011). The RVLM, however, appears to have a greater control over the regulation of BP, compared to regulation of thermogenesis and HR (Horiiuchii et al., 2006; Morrison et al., 2008). The neurochemical phenotype of the LepR-expressing neuron populations in the DMH is still debated (Lee et al., 2012). Further studies will be necessary to characterize the DMH circuits that contribute to leptin’s effects on blood pressure and to characterize the mechanisms by which these neurons modulate sympathetic outputs to the heart and peripheral blood vessels.

**Why Leptin—What about Insulin?**

Although results here strongly demonstrate the role of leptin in contributing to elevated BP in obesity, a number of other hormones that change in response to weight gain could contribute. As expected, we found that, compared to lean mice, plasma insulin was elevated in all obese models. Despite this increase in plasma insulin, it was only DIO mice that exhibited significantly elevated BP, and insulin levels were not correlated with HR or BP, suggesting that insulin contributes little to the chronic elevation of BP seen in obesity. Also, insulin sensitivity as measured by hyperinsulinemic euglycemic clamps is comparable in human MC4R deficiency versus obese controls despite a lower BP and reduced urinary catecholamine excretion in MC4R-deficient subjects (Greenfield et al., 2009). Therefore, our data do not support a role for insulin in mediating obesity-induced increases in BP.

In conclusion, these observations suggest that pharmacological approaches based on the modulation of leptin’s effects on specific subpopulations of neurons could represent a potentially useful therapeutic strategy for the treatment of obesity-associated hypertension and for the prevention of some obesity-associated cardiovascular disease.

**EXPERIMENTAL PROCEDURES**

All animal procedures were approved by Monash University animal ethics committee. All mice were housed in a controlled environment in which lights were on a 12 hr light/12 hr dark cycle; temperature and humidity remained constant. In experiments to examine the development of hypertension, 4-week-old male C57Bl/6J mice were implanted with radiotelemetry probes (DSL USA, model TA11PA-C10). These mice were allowed 2 weeks recovery post-surgery and, following baseline recordings, mice were split onto either chow (4.8% of fat, mouse and rat rodent chow diet, Specialty Feeds, Glen Forrest, Australia) or HFD (43% of fat, SF04-001, Specialty Feeds, Western Australia, Australia) for 20 weeks (140 days) in which recordings were taken every 13 to 15 days. After 20 weeks (140 days), the HFD fed mice were swapped onto a chow diet (4.8% of fat, SF04-001, Specialty Feeds, Western Australia, Australia) for 4 weeks. In all other experiments, male C57Bl/6J, leptin-deficient (ob/ob), LepR-deficient (db/db), LepR-deficient (LepRTB (Berglund et al., 2012), LepR flox, and LepR-Cre-YFP mice (Leshan et al., 2012) were placed on either a chow diet or HFD diet at 4 weeks of age and continuing for 20 consecutive weeks, after which mice were used for experiments. All mice were on a C57Bl/6J background. In all experiments, the animals’ BW and FI were monitored daily. Specific experimental procedures for radiotelemetry, pharmacological studies, genetic manipulations, and electrophysiological studies are detailed in the Supplemental Information.

**Human Studies**

All human studies were conducted according to the principles outlined in the Declaration of Helsinki and after approval by local ethical committees. All individuals or their parents (for children) gave written informed consent. Systolic and diastolic BP were measured in the rested, fasted state using wrist BP monitors (OMRON Healthcare, Hamburg, Germany) in leptin-deficient (n = 8) and leptin-receptor-deficient children (n = 12) (Farooqi et al., 2002, 2007). Control subjects were recruited from the Genetics of Obesity Study (GOOS) cohort. These control subjects had been tested for mutations in leptin, leptin receptor, and MC4R. Control subjects were aged AMR and BMI matched to leptin-deficient and leptin-receptor-deficient subjects (n = 42 and 48, respectively) (Wheeler et al., 2013).

**Adult Studies**

Leptin-deficient adult patients received pretreatment testing at the Pennington center, along with weight- and BP-matched control subjects. The leptin-deficient patients then received a 3 month treatment of recombinant leptin (Leptin [Amgen Inc., Thousand Oaks; Galgani et al., 2010]). Subjects were all provided a nutritionally balanced mixed diet during this period. Subjects then returned to the Pennington center for posttesting. Control subjects with “normal” leptin levels were administered a low-calorie diet (Galgani et al., 2010) for 9–20 weeks to cause the same weight loss and also returned to the Pennington center for posttesting. Mean ± SEM, t test, “p < 0.01. All subjects provided written informed consent. The study design was approved by the ethics committee of the Pennington Biomedical Research Center. Approval for leptin replacement included UCLA IRB approval (April 9, 2001) and FDA approval (IND application number 61690).

**Statistics**

Data are represented as mean ± SEM, and error bars also indicate SEM. p values were calculated by either unpaired or paired two-tailed Student’s t test, One-way ANOVA with Bonferroni post hoc test or two-way ANOVA with Bonferroni post hoc test. "p < 0.05, **p < 0.01, and ***p < 0.001.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Extended Experimental Procedures, five figures, and one table and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2014.10.058.

**AUTHOR CONTRIBUTIONS**

The design and performance of animal experiments was conducted by S.E.S., J.T.P., J.B., R.D.B., P.J.E., D.C.S., and M.A.C. Human clinical experiments were designed and performed by E.R., F.L.G., J.L., E.H., J.M.K., S.O., and J.M.K. Experiments were assisted by contributions from R.D., A.M.A., M.G.M., K.L.G., S.M.S., and J.K.E. Data analysis was conducted by S.E.S., J.T.P., J.B., R.D.B., P.J.E., D.C.S., and M.A.C. The manuscript was prepared by S.E.S., J.T.P., D.C.S., I.S.F., and M.A.C.
ACKNOWLEDGMENTS

This work was supported by the Heart Foundation of Australia (M.A.C. and S.E.S.), the National Health and Medical Research Council of Australia (1029188 to M.A.C. and 1063955 to D.C.S.), Monash University (S.E.S.), Pfizer Australia (M.A.C.), a NORC Center grant (P30DK072476) at the Pennington Biomedical Research Center (E.R., F.L.G., and J.L.), the Leverhulme Trust (J.T.P.), the Welcome Trust (082390/Z/07/Z) (I.S.F.), Medical Research Council (I.S.F.), NHMRC Biomedical Research Centre (I.S.F. and S.O.R.), and the Bernard Wolfe Health Neuroscience Fund (I.S.F.). We thank Professor Streamson Chua for the LepR flox mice. J.L. and I.S.F. treat patients with recombinant human leptin which is provided by BMS/AstraZeneca.

Received: May 27, 2014
Revised: August 31, 2014
Accepted: October 30, 2014
Published: December 4, 2014

REFERENCES


